Clinical Trial Update: Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial assessing different doses of BIM 23A760 in carcinoid syndrome was terminated with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Syndrome

Drugs mentioned

• BIM 23A760

Snippet

Sponsor: Ipsen | Conditions: Carcinoid Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2015-09-07